PET Scan Timing for Hodgkin Lymphoma on Nivolumab-AVD Treatment
For patients receiving Nivolumab plus AVD (N-AVD) for Hodgkin lymphoma, perform interim PET-CT after 2 cycles of treatment and end-of-treatment PET-CT after completing all planned cycles.
Recommended PET-CT Schedule
Interim PET-CT (iPET)
- Timing: After 2 cycles of N-AVD 1
- This follows the established ABVD paradigm where interim PET after 2 cycles has proven prognostic value
- The NIVAHL trial, which specifically evaluated N-AVD, performed interim staging after 2 cycles 2
- Deauville score ≤3 indicates negative/favorable response; ≥4 indicates positive/unfavorable response 1
End-of-Treatment PET-CT
- Timing: 3-8 weeks after completing all planned cycles 1, 3
- Optimal timing is 6-8 weeks post-treatment to minimize false-positives from inflammatory changes 3
- Minimum wait of 3 weeks is acceptable if earlier assessment is clinically necessary 3
Clinical Context for N-AVD
The evidence base for PET timing in N-AVD comes from extrapolation of ABVD protocols combined with specific N-AVD trial data:
NIVAHL Trial Experience 2:
- Patients received either 4 cycles of concomitant N-AVD or sequential nivolumab followed by N-AVD
- Interim staging occurred after 2 cycles of N-AVD (concomitant arm) or after 4 doses of nivolumab monotherapy (sequential arm)
- 100% of concomitant N-AVD patients achieved objective response at interim PET
- Final PET-CT was performed after completing all treatment
Older Adult N-AVD Study 4:
- Patients received 6 cycles of N-AVD
- PET-2 (after 2 cycles) was performed but was NOT predictive of progression-free survival or overall survival in this cohort
- This suggests that while interim PET should still be performed per standard protocols, treatment decisions in N-AVD may rely less heavily on interim results than with ABVD alone
Important Caveats
Timing Considerations
- Avoid PET within 2 weeks of chemotherapy to reduce false-positives from acute inflammation 3
- Avoid PET within 2-3 months of radiation therapy if RT is part of the treatment plan 3
- Growth factor administration can cause increased bone marrow uptake for up to 10 days 5
Interpretation Differences
Unlike ABVD where positive interim PET (Deauville ≥3-4) typically prompts treatment escalation 1, the role of treatment modification based on interim PET in N-AVD is less established. The NIVAHL trial showed excellent outcomes regardless of interim PET results 2, and the older adult study found PET-2 non-predictive 4.
Standard vs. N-AVD Protocols
Traditional ABVD guidelines recommend:
- Interim PET after 2 cycles for advanced-stage disease 1
- Treatment intensification (e.g., switch to BEACOPPescalated) for positive interim PET 1
However, with N-AVD, continue the planned regimen even if interim PET is positive, as the addition of nivolumab appears to overcome the negative prognostic significance of interim PET positivity seen with ABVD alone 2, 4.
Practical Algorithm
- Baseline PET-CT: Before starting N-AVD
- After Cycle 2: Interim PET-CT (iPET2)
- Document Deauville score
- Continue N-AVD regardless of result (unlike ABVD protocols)
- After completing planned cycles: End-of-treatment PET-CT
- Wait 6-8 weeks if possible (minimum 3 weeks)
- Defines final response status
This approach balances established PET-adapted strategies from ABVD trials with emerging evidence that N-AVD may not require the same response-adapted modifications.